Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 773-779

  Zinzani, Pier Luigi ^a   Magagnoli, Massimo ^a   Moretti, Luciano ^a   De Renzo, Amalia ^a   Battista, Raffaele ^a   Zaccaria, Alfonso ^a   Guardigni, Luciano ^a   Mazza, Patrizio ^a   Marra, Roberto ^a   Ronconi, Fioravante ^a   Lauta, Vito Michele ^a   Bendandi, Maurizio ^a   Gherlinzoni, Filippo ^a   Gentilini, Patrizia ^a   Ciccone, Fabrizio ^a   Cellini, Claudia ^a   Stefoni, Vittorio ^a   Ricciuti, Francesco ^a   Gobbi, Marco ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; IDARUBICIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HUMAN; IMMUNOCYTOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 0033953195     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.773     Document Type: Article

References (37)

1. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311: 1471-1475, 1984
2. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
3. Zucca E, Stein H, Coiffier B: European Lymphoma Task Force (ELTF): Report of the workshop on mantle cell lymphoma. Ann Oncol 5:507-511, 1994
4. McLaughlin P, Fuller LM, Velasquez WS, et al: Stage I-II follicular lymphoma: Treatment results for 76 patients. Cancer 58: 1596-1602, 1986
5. Zinzani PL, Magagnoli M, Gherlinzoni F, et al: To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center. Haematologica 83:502-507, 1998
6. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
7. Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
8. Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 109:790-794, 1992
9. Hochster HS, Kim K, Green MD, et al: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
10. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
11. Hiddeman W, Unterhalt M, Pott C, et al: Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 20:28-31, 1993
12. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
13. Pigaditou A, Rohatiner AZ, Whelan JS, et al: Fludarabine in low-grade lymphoma. Semin Oncol 20:24-27, 1993 (suppl 7)
14. Whelan JS, Davis CL, Rule S, et al: Fludarabine phosphate for the treatment of low-grade lymphoid malignancy. Br J Cancer 64:120-123, 1991
15. McLaughlin P, Hagemeister FB, Swan F, et al: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-579, 1994
16. Zinzani PL, Bendandi M, Tura S: FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 55:262-266, 1995
17. McLaughlin P, Hagemeister FB, Ramaguera JE, et al: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
18. Zinzani PL, Bendandi M, Magagnoli M, et al: Fludarabinemitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 8:379-383, 1997
19. Zinzani PL, Bendandi M, Gherlinzoni F, et al: FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma. Haematologica 81:168-171, 1996
20. Hochster H, Oken M, Bennet J, et al: Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non-Hodgkin's lymphomas (NHL)-ECOG 1491. Blood 84:383, 1994 (abstr)
21. Lazzarino M, Orlandi E, Montillo M, et al: Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 10:59-64, 1999
22. Harris NL, Jaffe ES, Stein H, et al: A proposal for an international consensus on the classification of lymphoid neoplasms. Blood 84:1361-1392, 1994
23. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971
24. Shipp M, Harrington D, Anderson J, et al: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:1471-1475, 1993
25. Oken M, Creech R, Tormey D: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
26. Cheson BD, Horning SJ, Coiffier B, et al: Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 17:1244-1253, 1999
27. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Freedman LS: Tables of the number of patients required in clinical trials using the log-rank test. Stat Med 1:121-129, 1982
29. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
30. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 22:209-222, 1959
31. Hagenbeek A, Eghbali H, Monfardini S, et al: Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stage III and IV low grade malignant non-Hodgkin's lymphomas: Preliminary results for a prospective, randomized phase III clinical trial in 381 patients. Blood 92:315a, 1998 (abstr)
32. Foran JM, Rohatiner AZS, Coiffier B, et al: Multicenter phase II of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999
33. Decaudin D, Bosq J, Tertian G, et al: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579-583, 1998
34. Zinzani PL, Magagnoli M, Moretti L, et al: Fludarabine-based chemotherapy in untreated mantle cell lymphomas: An encouraging experience in 29 patients. Haematologica 84:1002-1006, 1999
35. Keating MJ, McLaughlin P, Cabanillas F: Low-grade non-Hodgkin's lymphoma: Development of a new effective combination regimen (fludarabine, mitoxantrone, and dexamethasone; FND). Eur J Cancer Care (Engl) 6:21-26, 1997 (suppl 1)
36. Foussard C, Deconinck E, Desablens B, et al: A randomized trial of fludarabine, mitoxantrone (FM) versus doxorubicin, cyclophosphamide, vindesine, prednisone (CHEP) as first line treatment in patients with advanced low-grade lymphoma (LG-NHL): A multicenter study by GOLEAMS Group. Blood 92:316a, 1998 (abstr)
37. Gribben J, Neuberg D, Freedman A, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3454, 1993